ATH-1017
4 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
4
Ongoing
0
Recruiting
0
Completed
2
Sites
22
Countries
2
Endpoints
20
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 20 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 14 of 20 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
4
4
2
2
2
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
4 of 4
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| ACT-ADA Study of ATH-1017 in Mild to Moderate Alzheimer's Disease | ATH-1017 Alzheimer’s disease | mild-to-moderate AD / moderate AD dementia | Ph 2 | Completed | 13 | May 2022 | 1 | results |
| NCT04831281ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial) | ATH-1017 Lewy body dementia | Parkinson's disease dementia | Ph 2 | Terminated | 10 | Apr 2023 | - | results |
| NCT04886063Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease | ATH-1017 Alzheimer’s disease | Study partner/caregiver required | Ph 2/3 | Terminated | 1 | Oct 2024 | 1 | results |
| LIFT-ADATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease | ATH-1017 Alzheimer’s disease | mild-to-moderate AD / moderate AD dementia | Ph 2/3 | Completed | 1 | Jul 2024 | 2 | results |
Showing 1-4 of 4 trials